Phase 1 × Lymphoproliferative Disorders × Clear all
NCT06271252 2024-08-02

A Study to Evaluate the Safety, PK/PD of (OriCAR-017) in Subjects With RR/MM - RIGEL Study

OriCell Therapeutics Co., Ltd.

Phase 1 Recruiting
81 enrolled
NCT04309084 2023-02-16

Natural Killer Cell (CYNK-001) Infusions in Adults With Multiple Myeloma

Celularity Incorporated

Phase 1 Unknown
29 enrolled
NCT01273090 2014-01-30

Imetelstat Sodium in Treating Young Patients With Refractory or Recurrent Solid Tumors or Lymphoma

Children's Oncology Group

Phase 1 Completed
34 enrolled
NCT00324597 2013-09-17

AMG 706 and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma

National Cancer Institute (NCI)

Phase 1 Unknown
18 enrolled
NCT00734890 2012-03-16

Vandetanib and Bevacizumab in Treating Patients With Advanced Solid Tumors or Lymphoma

National Institutes of Health Clinical Center (CC)

Phase 1 Completed
18 enrolled
NCT00646139 2011-03-02

KX2-391 in Treating Patients With Advanced Solid Tumors or Lymphoma That Did Not Respond to Treatment

Roswell Park Cancer Institute

Phase 1 Completed
7 enrolled